In designing the study questions, the EPC consulted several Key Informants who represent the end-users of research. The EPC sought the Key Informant input on the priority areas for research and synthesis. Key Informants are not involved in the analysis of the evidence or the writing of the report. Therefore, in the end, study questions, design, methodological approaches, and/or conclusions do not necessarily represent the views of individual Key Informants.

Key Informants must disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Because of their role as end-users, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any conflicts of interest.

The list of Key Informants who provided input to this report follows:

• Andrew Avins, M.D., M.P.H.^*
  Division of Research
  Northern California Kaiser Permanente
  Oakland, CA
• Harris Foster, Jr., M.D.
  Department of Urology
  Yale School of Medicine
  New Haven, CT
• Chester Bernell Good, M.D., M.P.H., FACP
  School of Medicine
  University of Pittsburgh
  Pittsburgh, PA
• Ziya Kirkali, M.D.^*
  Program Director
  Division of Kidney, Urology and Hematology
  National Institute of Diabetes and Digestive and Kidney Diseases
  Bethesda, MD
• J. Kellogg Parsons, M.D., M.H.S.
  Department of Urology
  UCSD Comprehensive Cancer Center
  La Jolla, CA
• Justin Sherman, M.C.S., Pharm.D.^*
  School of Pharmacy
  University of Mississippi
  Jackson, MS

Footnotes

*

Provided input on Draft Report.